Virginie Beray-Berthat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Virginie Beray-Berthat has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Benoît Barsacq
EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France
1 shared publicationBruno Palmier
EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France
1 shared publicationBérard Coqueran
EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France
1 shared publication- Catherine Marchand-Leroux
Université Paris Descartes
1 shared publication Charlotte Abbou
EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France
1 shared publication- Dominique Lerouet
Université de Paris, Inserm UMR-S 1144—Optimisation Thérapeutique en Neuropsychopharmacologie, Faculté de Pharmacie de Paris, 4 Avenue de l’Observatoire, 75006 Paris, France
1 shared publication
Latest Publications
- 12 April 2018
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (12) , 9156-9168
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates, and increased risk of hemorrhagic transformations (HT). Experimental data showed that rt-PA enhances the post-ischemic activation of poly(ADP-ribose)polymerase (PARP) which in turn contributes to blood-brain barrier injury. The aim of the present study was to evaluate whether PJ34, a potent PARP inhibitor, improves poor reperfusion induced by delayed rt-PA administration, exerts vasculoprotective effects, and finally increases the therapeutic window of rt-PA. Stroke was induced by thrombin injection (0.75 UI in 1 μl) in the left middle cerebral artery (MCA) of male Swiss mice. Administration of rt-PA (0.9 mg kg−1) or saline was delayed for 4 h after ischemia onset. Saline or PJ34 (3 mg kg−1) was given intraperitoneally twice, just after thrombin injection and 3 h later, or once, 3 h after ischemia onset. Reperfusion was evaluated by laser Doppler, vascular inflammation by immunohistochemistry of vascular cell adhesion molecule-1 (VCAM-1) expression, and vasospasm by morphometric measurement of the MCA. Edema, cortical lesion, and sensorimotor deficit were evaluated. Treatment with PJ34 improved rt-PA-induced reperfusion and promoted vascular protection including reduction in vascular inflammation (decrease in VCAM-1 expression), HT, and MCA vasospasm. Additionally, the combined treatment significantly reduced brain edema, cortical lesion, and sensorimotor deficit. In conclusion, the combination of the PARP inhibitor PJ34 with rt-PA after cerebral ischemia may be of particular interest in order to improve thrombolysis with an extended therapeutic window.
- 12 April 2018
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (12) , 9156-9168
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates, and increased risk of hemorrhagic transformations (HT). Experimental data showed that rt-PA enhances the post-ischemic activation of poly(ADP-ribose)polymerase (PARP) which in turn contributes to blood-brain barrier injury. The aim of the present study was to evaluate whether PJ34, a potent PARP inhibitor, improves poor reperfusion induced by delayed rt-PA administration, exerts vasculoprotective effects, and finally increases the therapeutic window of rt-PA. Stroke was induced by thrombin injection (0.75 UI in 1 μl) in the left middle cerebral artery (MCA) of male Swiss mice. Administration of rt-PA (0.9 mg kg−1) or saline was delayed for 4 h after ischemia onset. Saline or PJ34 (3 mg kg−1) was given intraperitoneally twice, just after thrombin injection and 3 h later, or once, 3 h after ischemia onset. Reperfusion was evaluated by laser Doppler, vascular inflammation by immunohistochemistry of vascular cell adhesion molecule-1 (VCAM-1) expression, and vasospasm by morphometric measurement of the MCA. Edema, cortical lesion, and sensorimotor deficit were evaluated. Treatment with PJ34 improved rt-PA-induced reperfusion and promoted vascular protection including reduction in vascular inflammation (decrease in VCAM-1 expression), HT, and MCA vasospasm. Additionally, the combined treatment significantly reduced brain edema, cortical lesion, and sensorimotor deficit. In conclusion, the combination of the PARP inhibitor PJ34 with rt-PA after cerebral ischemia may be of particular interest in order to improve thrombolysis with an extended therapeutic window.